Importance:
International resuscitation guidelines recommend targeted temperature management (TTM) at 33°C to 36°C in unconscious patients with out-of-hospital cardiac arrest for at least 24 hours, but the optimal duration of TTM is uncertain.
Objective:
To determine whether TTM at 33°C for 48 hours results in better neurologic outcomes compared with currently recommended, standard, 24-hour TTM.
Design, Setting, And Participants:
This was an international, investigator-initiated, blinded-outcome-assessor, parallel, pragmatic, multicenter, randomized clinical superiority trial in 10 intensive care units (ICUs) at 10 university hospitals in 6 European countries. Three hundred fifty-five adult, unconscious patients with out-of-hospital cardiac arrest were enrolled from February 16, 2013, to June 1, 2016, with final follow-up on December 27, 2016.
Interventions:
Patients were randomized to TTM (33 ± 1°C) for 48 hours (n = 176) or 24 hours (n = 179), followed by gradual rewarming of 0.5°C per hour until reaching 37°C.
Main Outcomes And Measures:
The primary outcome was 6-month neurologic outcome, with a Cerebral Performance Categories (CPC) score of 1 or 2 used to define favorable outcome. Secondary outcomes included 6-month mortality, including time to death, the occurrence of adverse events, and intensive care unit resource use.
Results:
In 355 patients who were randomized (mean age, 60 years; 295 [83%] men), 351 (99%) completed the trial. Of these patients, 69% (120/175) in the 48-hour group had a favorable outcome at 6 months compared with 64% (112/176) in the 24-hour group (difference, 4.9%; 95% CI, -5% to 14.8%; relative risk [RR], 1.08; 95% CI, 0.93-1.25; P = .33). Six-month mortality was 27% (48/175) in the 48-hour group and 34% (60/177) in the 24-hour group (difference, -6.5%; 95% CI, -16.1% to 3.1%; RR, 0.81; 95% CI, 0.59-1.11; P = .19). There was no significant difference in the time to mortality between the 48-hour group and the 24-hour group (hazard ratio, 0.79; 95% CI, 0.54-1.15; P = .22). Adverse events were more common in the 48-hour group (97%) than in the 24-hour group (91%) (difference, 5.6%; 95% CI, 0.6%-10.6%; RR, 1.06; 95% CI, 1.01-1.12; P = .04). The median length of intensive care unit stay (151 vs 117 hours; P < .001), but not hospital stay (11 vs 12 days; P = .50), was longer in the 48-hour group than in the 24-hour group.
Conclusions And Relevance:
In unconscious survivors from out-of-hospital cardiac arrest admitted to the ICU, targeted temperature management at 33°C for 48 hours did not significantly improve 6-month neurologic outcome compared with targeted temperature management at 33°C for 24 hours. However, the study may have had limited power to detect clinically important differences, and further research may be warranted.
Trial Registration:
clinicaltrials.gov Identifier: NCT01689077.
Citing Articles
Plasma brain-related biomarkers and potential therapeutic targets in pediatric ECMO.
Hong S, De Souza B, Penberthy K, Hwang L, Procaccini D, Kheir J
Neurotherapeutics. 2025; 22(1):e00521.
PMID: 39765416
PMC: 11840354.
DOI: 10.1016/j.neurot.2024.e00521.
Application of high-quality targeted temperature management guided by multimodal brain monitoring in brain protection of patients with cardiac arrest: A case series.
Xia W, Ai M, Ma X, Hu C, Peng Q, Zhao C
Medicine (Baltimore). 2024; 103(51):e40943.
PMID: 39705417
PMC: 11666168.
DOI: 10.1097/MD.0000000000040943.
A review on targeted temperature management for cardiac arrest and traumatic brain injury.
Ito H, Hosomi S, Nishida T, Nakamura Y, Iba J, Ogura H
Front Neurosci. 2024; 18:1397300.
PMID: 39544908
PMC: 11560895.
DOI: 10.3389/fnins.2024.1397300.
Optimal Targeted Temperature Management for Patients with Post-Cardiac Arrest Syndrome.
Yagi T, Tachibana E, Atsumi W, Kuronuma K, Iso K, Hayashida S
Medicina (Kaunas). 2024; 60(10).
PMID: 39459362
PMC: 11509509.
DOI: 10.3390/medicina60101575.
Does targeted temperature management at 33 °C improve outcome after cardiac arrest?.
Skrifvars M, Abella B
Curr Opin Crit Care. 2024; 30(6):618-623.
PMID: 39445488
PMC: 11540270.
DOI: 10.1097/MCC.0000000000001214.
Targeted Temperature Management for Out-of-Hospital Cardiac Arrest Survivors.
Ramzan N, Dhillon R, Anwer M, Hashmat M, Shahjahan K, Asif T
Cureus. 2024; 16(9):e69204.
PMID: 39268021
PMC: 11392523.
DOI: 10.7759/cureus.69204.
SMYD5 is a regulator of the mild hypothermia response.
Rafnsdottir S, Jang K, Halldorsdottir S, Vinod M, Tomasdottir A, Moller K
Cell Rep. 2024; 43(8):114554.
PMID: 39083378
PMC: 11401508.
DOI: 10.1016/j.celrep.2024.114554.
Influence of Cooling duration on Efficacy in Cardiac Arrest Patients (ICECAP): study protocol for a multicenter, randomized, adaptive allocation clinical trial to identify the optimal duration of induced hypothermia for neuroprotection in comatose,....
Meurer W, Schmitzberger F, Yeatts S, Ramakrishnan V, Abella B, Aufderheide T
Trials. 2024; 25(1):502.
PMID: 39044295
PMC: 11264458.
DOI: 10.1186/s13063-024-08280-w.
Influence of Cooling duration on Efficacy in Cardiac Arrest Patients (ICECAP): study protocol for a multicenter, randomized, adaptive allocation clinical trial to identify the optimal duration of induced hypothermia for neuroprotection in comatose,....
Meurer W, Schmitzberger F, Yeatts S, Ramakrishnan V, Abella B, Aufderheide T
Res Sq. 2024; .
PMID: 38947064
PMC: 11213199.
DOI: 10.21203/rs.3.rs-4033108/v1.
Association between sub-phenotypes identified using latent class analysis and neurological outcomes in patients with out-of-hospital cardiac arrest in Japan.
Tamura H, Yasuda H, Oishi T, Shinzato Y, Amagasa S, Kashiura M
BMC Cardiovasc Disord. 2024; 24(1):303.
PMID: 38877462
PMC: 11177357.
DOI: 10.1186/s12872-024-03975-z.
A Comprehensive Review and Practical Guide of the Applications of Evoked Potentials in Neuroprognostication After Cardiac Arrest.
Portell Penades E, Alvarez V
Cureus. 2024; 16(3):e57014.
PMID: 38681279
PMC: 11046378.
DOI: 10.7759/cureus.57014.
Comparative before-after study of fever prevention versus targeted temperature management following out-of-hospital cardiac arrest.
Leadbeater P, Warren A, Adekunle E, Fielden H, Barry J, Proudfoot A
Resusc Plus. 2024; 17:100538.
PMID: 38205148
PMC: 10776978.
DOI: 10.1016/j.resplu.2023.100538.
Dysnatremia at ICU admission and functional outcome of cardiac arrest: insights from four randomised controlled trials.
Lascarrou J, Ermel C, Cariou A, Laitio T, Kirkegaard H, Soreide E
Crit Care. 2023; 27(1):472.
PMID: 38041177
PMC: 10693108.
DOI: 10.1186/s13054-023-04715-z.
Soluble Urokinase-Type Plasminogen Activator Receptor in Comatose Survivors After Out-of-Hospital Cardiac Arrest Treated with Targeted Temperature Management.
Bro-Jeppesen J, Grejs A, Andersen O, Jeppesen A, Duez C, Kirkegaard H
Ther Hypothermia Temp Manag. 2023; 14(4):243-251.
PMID: 37910781
PMC: 11665269.
DOI: 10.1089/ther.2023.0039.
Temperature management in the intensive care unit: a practical survey from China.
Meng L, Wang C, Liu X, Bi Y, Zhu K, Yue Y
Libyan J Med. 2023; 18(1):2275416.
PMID: 37905303
PMC: 11018322.
DOI: 10.1080/19932820.2023.2275416.
General Critical Care, Temperature Control, and End-of-Life Decision Making in Patients Resuscitated from Cardiac Arrest.
Chalkias A, Adamos G, Mentzelopoulos S
J Clin Med. 2023; 12(12).
PMID: 37373812
PMC: 10298925.
DOI: 10.3390/jcm12124118.
SMYD5 is a regulator of the mild hypothermia response.
Rafnsdottir S, Jang K, Halldorsdottir S, Vinod M, Tomasdottir A, Moller K
bioRxiv. 2023; .
PMID: 37333301
PMC: 10274674.
DOI: 10.1101/2023.05.11.540170.
Higher versus lower blood pressure targets after cardiac arrest: A meta-analysis of randomized controlled trials.
Ahmad Cheema H, Shafiee A, Teymouri Athar M, Akhondi A, Shahid A, Ghafoor M
Indian Heart J. 2023; 75(4):304-307.
PMID: 37328138
PMC: 10421983.
DOI: 10.1016/j.ihj.2023.06.005.
Hypothermia for neuroprotection in adults after cardiac arrest.
Arrich J, Schutz N, Oppenauer J, Vendt J, Holzer M, Havel C
Cochrane Database Syst Rev. 2023; 5:CD004128.
PMID: 37217440
PMC: 10202224.
DOI: 10.1002/14651858.CD004128.pub5.
Optimal Timing of Targeted Temperature Management for Post-Cardiac Arrest Syndrome: Is Sooner Better?.
Wang I, Wang C, Chen C, Yang S, Chen C, Huang Y
J Clin Med. 2023; 12(7).
PMID: 37048710
PMC: 10095041.
DOI: 10.3390/jcm12072628.